[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-365849-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-365849-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ezh2-a-crucial-competing-endogenous-rna-in-cancer-research-a-scoping-review","EZH2 - A Crucial Competing Endogenous RNA in Cancer - Research - A Scoping Review","","Scoping review of competing endogenous RNA (ceRNA) networks in cancer focusing on EZH2 as a ceRNA with dual oncogenic and tumor-suppressive roles. Searches across multiple online databases identified 66 experimentally validated EZH2-containing axes across human cancers, spanning 30 miRNAs, 32 lncRNAs, 9 mRNAs, and 14 circRNAs. Recurrent axes included SPRY4‑IT1‑miR‑101‑3p‑EZH2 and XIST‑miR‑101‑3p‑EZH2, with frequent miRNAs such as miR‑101‑3p, miR‑144‑3p, and miR‑124‑3p. Results highlight diverse EZH2 ceRNA competitors and propose therapeutic targeting potential pending further clarification of clinical utility.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ezh2-a-crucial-competing-endogenous-rna-in-cancer-research-a-scoping-review/365849/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ezh2-a-crucial-competing-endogenous-rna-in-cancer-research-a-scoping-review/365849.png","ImageObject",300,407,{"name":42,"@type":43},"Angel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the scoping review investigate about EZH2 in cancer?","Question",{"text":63,"@type":64},"It summarizes experimentally validated competing endogenous RNA (ceRNA) axes involving EZH2 across human cancers, emphasizing EZH2’s role as a potential therapeutic target.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many EZH2-containing ceRNA axes were identified?",{"text":68,"@type":64},"The review identified 66 unique axes involving 30 miRNAs, 32 lncRNAs, 9 mRNAs, and 14 circRNAs.",{"name":70,"@type":61,"acceptedAnswer":71},"Which ceRNA axes and miRNAs were observed most frequently?",{"text":72,"@type":64},"Recurrent axes included SPRY4‑IT1‑miR‑101‑3p‑EZH2 and XIST‑miR‑101‑3p‑EZH2. Frequent miRNAs included miR‑101‑3p, miR‑144‑3p, and miR‑124‑3p.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},365849,1790648234,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},687207412472,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","| Review Article |\n| --- |\n|  |\n\nEZH2: A Crucial Competing Endogenous RNA in Cancer  \nResearch‑A Scoping Review  \nSadra Salehi‑Mazandarani1, Sharareh Mahmoudian‑Hamedani1, Ziba Farajzadegan2, Parvaneh Nikpour1,3  \n1Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran, 2Department of Community and Family Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran, 3Department of Psychiatry and Neurochemistry, Institute of Neuroscience and  \nPhysiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden  \nAbstract  \nRecently, research on the competing endogenous RNAs (ceRNAs) in cancer has been in full swing, emphasizing their importance as critical RNAs in cancer progression. Enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) is a ceRNA that has been introduced asa potential therapeutic target in many cancers. Due to EZH2’s dual role as an oncogene and tumor suppressor in cancer, a more thorough exploration of its ceRNA functions may enhance clinical cancer treatment approaches. In the current scoping review, we searched several online databases to identify experimentally validated ceRNA axes, including EZH2 in human cancers. We identified 66 unique axes consisting of 30 microRNAs (miRNAs), 32 long non‑coding RNAs (lncRNAs), 9 messenger RNAs (mRNAs), and 14 circular RNAs (circRNAs). Notably, SPRY4‑IT1 ‑ miR‑101‑3p ‑ EZH2 and XIST ‑ miR‑101‑3p ‑ EZH2 were recurrent axes observed in multiple cancer types. Among the most frequent miRNAs were miR‑101‑3p, miR‑144‑3p and miR‑124‑3p, and ceRNAs including SPRY4‑IT1, XIST, SNHG6, HOXA11‑AS, MALAT1, and TUG1 emerged as frequent competitors of EZH2 for miRNA binding. This scoping review highlights the diversity of EZH2‑containing ceRNA axes in cancer, suggesting their potential as therapeutic targets. Further studies are needed to clarify their roles and clinical utility.  \nKeywords: Enhancer of zeste 2 polycomb repressive complex 2 subunit; neoplasms; RNA, competitive endogenous; RNA, untranslated  \nAddress for correspondence: Dr. Parvaneh Nikpour, Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.  \nE‑mail: [pnikpour@med.mui.ac.ir](pnikpour@med.mui.ac.ir)  \nSubmitted: 10‑Nov‑2024; Revised: 18‑Feb‑2025; Accepted: 19‑Feb‑2025; Published: 31‑May‑2025  \nIntroductIon  \nEZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which suppresses gene expression by methylation of lysine 27 of histone 3 (H3K27) .[1] This epigenetic modification is thought to silence more than 200 tumor suppressor genes.[1] In addition, EZH2 can alsomethylate non‑histone proteins and affect their transcriptional activity. For instance, EZH2 methylatesthe GATA4 transcription factor and reduces its acetylation by p300, resulting in the inhibition of GATA4‑mediated transcription. [2] Moreover, EZH2 can also activate downstream genes in a PRC2‑independent way by methylation of non‑histone proteins. [3] Through these  \n\n| Access this article online |  |\n| --- | --- |\n| Quick Response Code:\u003Cbr>| Website:\u003Cbr>[www.advbiores.net](www.advbiores.net) |\n|  | DOI:\u003Cbr>10.4103/abr.abr_561_24 |\n\nmechanisms, EZH2 is involved in various cellular processes, such as cell cycle regulation, autophagy, apoptosis, DNA repair, and cellular senescence. EZH2 is also associated with many diseases, especially cancer.[4]  \nEZH2 is overexpressed in many types of cancer where it disturbs various cellular processes such as proliferation, apoptosis, migration, and invasion.[5] Moreover, EZH2 is subjected to post‑translational modifications that modulate its function and activity in cancer. For example, the phosphorylation ofEZH2 can either promote (pT350‑EZH2) or inhibit (pT487‑EZH2) cell invasion and metastasis. O‑GlcNAcylation, acetylation, and methylation of EZH2 affect the pro","cbCaipGiaJzvs6Ua","https://ap.wps.com/l/cbCaipGiaJzvs6Ua","pdf",2163117,17,"English","# Abstract\n# Introduction\n## EZH2 function and epigenetic role\n## EZH2 in cancer progression\n## Regulation of EZH2 by microRNAs","[{\"question\":\"What does the scoping review investigate about EZH2 in cancer?\",\"answer\":\"It summarizes experimentally validated competing endogenous RNA (ceRNA) axes involving EZH2 across human cancers, emphasizing EZH2’s role as a potential therapeutic target.\"},{\"question\":\"How many EZH2-containing ceRNA axes were identified?\",\"answer\":\"The review identified 66 unique axes involving 30 miRNAs, 32 lncRNAs, 9 mRNAs, and 14 circRNAs.\"},{\"question\":\"Which ceRNA axes and miRNAs were observed most frequently?\",\"answer\":\"Recurrent axes included SPRY4‑IT1‑miR‑101‑3p‑EZH2 and XIST‑miR‑101‑3p‑EZH2. Frequent miRNAs included miR‑101‑3p, miR‑144‑3p, and miR‑124‑3p.\"}]","EZH2 - A Crucial Competing Endogenous RNA in Cancer - Research - A Scoping Review | PDF",1790162621,43,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9555d0283c4da750152d6cd897cbe808.webp",983,1272,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99281126b0b589af92c97edd9a3763e9.webp",982,1270,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6cd5dafacac811ae488823330b4fbe66.webp",981,1269,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1767dd47b68423f39bf445cc59be1f37.webp",980,1268]